ECOR Valuation

electroCore, Inc.

Add to Watchlist

Advanced Chart

5.080

-0.13(-2.495%)1D

Overview
Forecast
Valuation
Earnings

ECOR Relative Valuation

ECOR's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, ECOR is overvalued; if below, it's undervalued.

Historical Valuation

electroCore, Inc. (ECOR) is now in the Undervalued zone, suggesting that its current forward PS ratio of 1.11 is considered Undervalued compared with the five-year average of -4.74. The fair price of electroCore, Inc. (ECOR) is between 7.36 to 13.53 according to relative valuation methord. Compared to the current price of 5.21 USD , electroCore, Inc. is Undervalued By 29.21%.

Relative Value

Fair Zone

7.36-13.53

Current Price：5.21

29.21%

Undervalued

-4.57

Trailing

Forward

0.00

EV/EBITDA

electroCore, Inc.. (ECOR) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is -2.58. The thresholds are as follows: Strongly Undervalued below -11.19, Undervalued between -11.19 and -6.88, Fairly Valued between 1.73 and -6.88, Overvalued between 1.73 and 6.03, and Strongly Overvalued above 6.03. The current Forward EV/EBITDA of 0.00 falls within the Historic Trend Line -Fairly Valued range.

-3.13

EV/EBIT

electroCore, Inc.. (ECOR) has a current EV/EBIT of -3.13. The 5-year average EV/EBIT is -2.90. The thresholds are as follows: Strongly Undervalued below -9.42, Undervalued between -9.42 and -6.16, Fairly Valued between 0.35 and -6.16, Overvalued between 0.35 and 3.61, and Strongly Overvalued above 3.61. The current Forward EV/EBIT of -3.13 falls within the Historic Trend Line -Fairly Valued range.

1.03

electroCore, Inc.. (ECOR) has a current PS of 1.03. The 5-year average PS is 5.01. The thresholds are as follows: Strongly Undervalued below -5.41, Undervalued between -5.41 and -0.20, Fairly Valued between 10.22 and -0.20, Overvalued between 10.22 and 15.43, and Strongly Overvalued above 15.43. The current Forward PS of 1.03 falls within the Historic Trend Line -Fairly Valued range.

0.00

P/OCF

electroCore, Inc.. (ECOR) has a current P/OCF of 0.00. The 5-year average P/OCF is -8.93. The thresholds are as follows: Strongly Undervalued below -51.46, Undervalued between -51.46 and -30.19, Fairly Valued between 12.33 and -30.19, Overvalued between 12.33 and 33.60, and Strongly Overvalued above 33.60. The current Forward P/OCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.

-10.06

P/FCF

electroCore, Inc.. (ECOR) has a current P/FCF of -10.06. The 5-year average P/FCF is -2.27. The thresholds are as follows: Strongly Undervalued below -21.70, Undervalued between -21.70 and -11.99, Fairly Valued between 7.44 and -11.99, Overvalued between 7.44 and 17.15, and Strongly Overvalued above 17.15. The current Forward P/FCF of -10.06 falls within the Historic Trend Line -Fairly Valued range.

electroCore, Inc. (ECOR) has a current Price-to-Book (P/B) ratio of 33.34. Compared to its 3-year average P/B ratio of 6.30 , the current P/B ratio is approximately 429.28% higher. Relative to its 5-year average P/B ratio of 4.68, the current P/B ratio is about 612.18% higher. electroCore, Inc. (ECOR) has a Forward Free Cash Flow (FCF) yield of approximately -18.82%. Compared to its 3-year average FCF yield of -42.36%, the current FCF yield is approximately -55.56% lower. Relative to its 5-year average FCF yield of -36.80% , the current FCF yield is about -48.85% lower.

34.95

P/B

Median3y

6.30

Median5y

4.68

-20.32

FCF Yield

Median3y

-42.36

Median5y

-36.80

Competitors Valuation Multiple

The average P/S ratio for ECOR's competitors is 2.82, providing a benchmark for relative valuation. electroCore, Inc. Corp (ECOR) exhibits a P/S ratio of 1.03, which is -63.35% above the industry average. Given its robust revenue growth of 20.23%, this premium appears sustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

Vicarious Surgical Inc

Loss

37.98M

NMTC.O

NeuroOne Medical Technologies Corp

Firefly Neuroscience Inc

X T L Biopharmaceuticals Ltd

0.04

1.09B

Performance Decomposition

Market capitalization of ECOR decreased by 16.03% over the past 1 year. The primary factor behind the change was an increase in Revenue Growth from 6.14M to 7.38M.

The secondary factor is the Margin Expansion, contributed 15.01%to the performance.

Overall, the performance of ECOR in the past 1 year is driven by Revenue Growth. Which is more sustainable.

20.23%

6.14M → 7.38M

Revenue Growth

15.01%

-43.25 → -49.74

Margin Expansion

-51.27%

-6.63 → -3.23

P/E Change

-16.03%